Table 4 Change in immunostaining of carcinoma cells between pre-treatment and post-treatment, assessed by semi-quantitative analysis (n = 92)
| Â | Groupa | P-value | ||
|---|---|---|---|---|
I (n = 33) | II (n = 30) | III (n = 29) | ||
Bax immunostaining, n (%) | Â | Â | Â | Â |
 Decrease | 0 (0.0) | 0 (0.0) | 1 (3.4) | <0.001b |
 No change | 5 (15.2) | 3 (10.0) | 27 (93.1) | |
 Increase | 28 (84.8) | 27 (90.0) | 1 (3.4) | |
Bcl-2 immunostaining, n (%) | Â | Â | Â | Â |
 Decrease | 30 (90.9) | 24 (80.0) | 8 (27.6) | <0.001b |
 No change | 3 (9.1) | 4 (13.3) | 18 (62.1) | |
 Increase | 0 (0.0) | 2 (6.7) | 3 (10.3) | |